CytomX Historical Income Statement
| CTMX Stock | USD 0.87 0 0.34% |
Historical analysis of CytomX Therapeutics income statement accounts such as Interest Expense of 2.1 M, Selling General Administrative of 28.8 M or Total Revenue of 54.2 M can show how well CytomX Therapeutics performed in making a profits. Evaluating CytomX Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of CytomX Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining CytomX Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CytomX Therapeutics is a good buy for the upcoming year.
CytomX |
About CytomX Income Statement Analysis
CytomX Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to CytomX Therapeutics shareholders. The income statement also shows CytomX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
CytomX Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts CytomX Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of CytomX Therapeutics minus its cost of goods sold. It is profit before CytomX Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of CytomX Therapeutics. It is also known as CytomX Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from CytomX Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of CytomX Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from CytomX Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into CytomX Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CytomX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.At this time, CytomX Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 115.4 M in 2024, whereas Interest Expense is likely to drop slightly above 2.1 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 69.6M | 53.2M | 99.0M | 53.9M | Total Revenue | 69.6M | 53.2M | 101.2M | 54.2M |
CytomX Therapeutics income statement Correlations
Click cells to compare fundamentals
CytomX Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
CytomX Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 2.6M | 5.5M | 2.7M | 2.4M | 2.2M | 2.3M | |
| Interest Expense | 10.8M | 1.8M | 172K | 2.0M | 2.3M | 2.1M | |
| Selling General Administrative | 36.8M | 36.0M | 39.2M | 42.8M | 30.0M | 28.8M | |
| Total Revenue | 57.5M | 100.4M | 69.6M | 53.2M | 101.2M | 54.2M | |
| Gross Profit | 57.5M | 100.4M | 69.6M | 53.2M | 99.0M | 53.9M | |
| Other Operating Expenses | 168.4M | 149.0M | 153.4M | 154.5M | 107.7M | 115.4M | |
| Operating Income | (110.9M) | (48.6M) | (83.8M) | (101.3M) | (6.5M) | (6.8M) | |
| Ebit | (110.9M) | (83.4M) | (83.8M) | (101.3M) | (6.5M) | (6.8M) | |
| Research Development | 131.6M | 112.9M | 114.2M | 111.6M | 77.7M | 86.7M | |
| Ebitda | (108.3M) | (78.0M) | (81.1M) | (98.9M) | (4.3M) | (4.5M) | |
| Cost Of Revenue | 105.5M | 0.0 | 5.8M | 5.9M | 2.2M | 2.1M | |
| Total Operating Expenses | 168.4M | 149.0M | 153.4M | 154.5M | 107.7M | 115.4M | |
| Income Before Tax | (102.7M) | (46.8M) | (83.6M) | (99.3M) | 3.3M | 3.5M | |
| Total Other Income Expense Net | 8.2M | 1.8M | 172K | 2.0M | 9.8M | 10.3M | |
| Net Income | (102.2M) | (32.9M) | (80.6M) | (97.3M) | (569K) | (597.5K) | |
| Income Tax Expense | (427K) | (13.9M) | (3.0M) | (2.0M) | 3.9M | 4.1M | |
| Net Income From Continuing Ops | (102.2M) | (32.9M) | (83.6M) | (115.9M) | (10.2M) | (10.7M) | |
| Net Income Applicable To Common Shares | (102.2M) | (32.9M) | (83.6M) | (115.9M) | (104.3M) | (109.5M) | |
| Tax Provision | 14.3M | (427K) | (13.9M) | 0.0 | 2.8M | 3.0M | |
| Interest Income | 8.4M | 1.8M | 255K | 1.7M | 8.1M | 4.1M | |
| Net Interest Income | 8.4M | 1.8M | 255K | 1.7M | 8.1M | 4.3M | |
| Non Operating Income Net Other | 7.6M | 8.2M | 1.8M | 172K | 154.8K | 147.1K | |
| Reconciled Depreciation | 2.6M | 2.6M | 2.7M | 2.4M | 2.3M | 2.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.